HEALTHCARE
Analysts remain positive on Teva
The company's 2025 guidance sent its share price tumbling, but analysts stress its investment in its innovative pipeline and debt reduction.
Trial success boosts NovoCure
The company's share price is up over 30% after it announced the results of the trial of its product in treating pancreatic cancer.